Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Recombinant DNA01:09

Recombinant DNA

Overview
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ACLY inhibition promotes tumour immunity and suppresses liver cancer.

Nature·2025
Same author

Mapping the intersection of demographics, behavior, and government response to the COVID-19 pandemic: an observational cohort study.

BMC global and public health·2025
Same author

Thermostabilization of a model viral-vectored oral thin film vaccine.

International journal of pharmaceutics·2025
Same author

Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.

Allergy·2023
Same author

Proceedings of the immune thrombocytopenia summit: new concepts in mechanisms, diagnosis, and management.

Research and practice in thrombosis and haemostasis·2023
Same author

Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections.

Viruses·2021
Same journal

Anaphylaxis: State-of-the-Art.

Immunology and allergy clinics of North America·2026
Same journal

Upending Impending Doom.

Immunology and allergy clinics of North America·2026
Same journal

Mast Cell Activation Syndrome and Mimickers.

Immunology and allergy clinics of North America·2026
Same journal

Hereditary Alpha-Tryptasemia (HαT) as a Risk Modifier for Severe Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Emerging Therapies for Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Novel Epinephrine Delivery Devices.

Immunology and allergy clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Peptide and recombinant immunotherapy.

Mark Larché1

  • 1Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, HSC 4H20, 1200 Main Street West, Hamilton, ON L8N 3Z5, Canada. larche@mcmaster.ca

Immunology and Allergy Clinics of North America
|May 3, 2011
PubMed
Summary
This summary is machine-generated.

The transition to standardized recombinant/synthetic hypoallergenic approaches is inevitable for allergen immunotherapy. This standardization will enable accurate assessment of treatment effects and reduce adverse events during therapy.

More Related Videos

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells
13:58

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

Published on: October 22, 2012

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Related Experiment Videos

Last Updated: Jun 2, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells
13:58

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

Published on: October 22, 2012

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Area of Science:

  • Immunology
  • Allergy Research
  • Biotechnology

Background:

  • Current allergen immunotherapy lacks standardization, leading to variability in treatment efficacy and safety.
  • Allergic adverse events during therapy necessitate safer and more predictable treatment options.
  • The complexity of allergen mixtures hinders direct comparison between different immunotherapy studies.

Purpose of the Study:

  • To advocate for the standardization of allergen immunotherapy through recombinant/synthetic hypoallergenic approaches.
  • To highlight the potential of using limited allergen panels or epitopes for effective therapy.
  • To emphasize the benefits of standardized products for blinded, comparative immunotherapy research.

Main Methods:

  • Review of existing evidence supporting the efficacy of limited allergen panels.
  • Analysis of the implications of standardization for study design and blinding.
  • Discussion of the transition towards recombinant and synthetic hypoallergenic agents.

Main Results:

  • Evidence suggests that effective allergen immunotherapy can be achieved with a reduced set of allergens or epitopes.
  • Standardized products facilitate direct comparison of study outcomes.
  • True blinding in immunotherapy studies becomes feasible with standardized interventions.

Conclusions:

  • Standardized recombinant/synthetic hypoallergenic approaches are essential for the future of allergen immunotherapy.
  • These approaches promise to reduce allergic adverse events and improve treatment safety.
  • Standardization will enable more rigorous and reliable assessment of immunotherapy efficacy.